PMID- 31469217
OWN - NLM
STAT- MEDLINE
DCOM- 20210520
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 22
IP  - 1
DP  - 2020 Jan
TI  - Comparison of lixisenatide in combination with basal insulin vs other insulin 
      regimens for the treatment of patients with type 2 diabetes inadequately 
      controlled by basal insulin: Systematic review, network meta-analysis and 
      cost-effectiveness analysis.
PG  - 107-115
LID - 10.1111/dom.13871 [doi]
AB  - AIMS: To evaluate the comparative efficacy and safety of lixisenatide combined 
      with basal insulin (BI) vs intensive premix insulin (premix), BI plus prandial 
      insulin with the main meal (basal-plus) or progressively covering all meals 
      (basal-bolus) in patients with type 2 diabetes mellitus (T2DM) inadequately 
      controlled by BI, and the long-term cost-effectiveness of lixisenatide from a 
      Chinese healthcare system perspective. MATERIALS AND METHODS: Randomized 
      controlled trials (RCTs) published between 1998 and 2018 were systematically 
      searched. The clinical efficacy and safety of each treatment were compared by 
      network meta-analysis (NMA). The IQVIA CORE Diabetes Model was used to estimate 
      the lifetime quality-adjusted life-years (QALYs) and direct medical costs of 
      patients treated with different strategies. RESULTS: Eight RCTs were finally 
      included. Lixisenatide plus BI showed a similar reduction in HbA1c from baseline 
      compared with premix, basal-plus and basal-bolus. There were significant 
      differences in the change of body weight in favour of lixisenatide plus BI 
      compared with the three insulin regimens. The risk of symptomatic hypoglycaemia 
      of lixisenatide plus BI was significantly lower compared with premix and 
      basal-bolus. Lixisenatide plus BI was cost-effective compared with premix, 
      basal-plus and basal-bolus with incremental cost-effectiveness ratios of Chinese 
      yuan (CNY) 87 219, 48 173 and 48 670 per QALY gained, respectively, under the 
      threshold of three times the gross domestic product (GDP) per capita in China. 
      CONCLUSIONS: Lixisenatide plus BI shows a similar HbA1c reduction compared with 
      insulin regimens, accompanied by lower risk of hypoglycaemia and greater body 
      weight reduction. It is a cost-effective treatment alternative for patients with 
      T2DM inadequately controlled by BI in China.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Men, Peng
AU  - Men P
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
AD  - Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 
      China.
FAU - Qu, Shuli
AU  - Qu S
AD  - Real World Insights, IQVIA, Shanghai, China.
FAU - Luo, Wenting
AU  - Luo W
AD  - Real World Insights, IQVIA, Shanghai, China.
FAU - Li, Chaoyun
AU  - Li C
AD  - Health Economics & Outcome Research, Shanghai, China.
FAU - Zhai, Suodi
AU  - Zhai S
AUID- ORCID: 0000-0003-2220-359X
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
AD  - Institute for Drug Evaluation, Peking University Health Science Center, Beijing, 
      China.
LA  - eng
GR  - Sanofi China/International
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20191007
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Peptides)
RN  - 74O62BB01U (lixisenatide)
SB  - IM
MH  - China/epidemiology
MH  - Cost-Benefit Analysis
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin/*administration & dosage
MH  - Network Meta-Analysis
MH  - Peptides/*administration & dosage
OTO - NOTNLM
OT  - antidiabetic drug
OT  - cost-effectiveness
OT  - glucagon-like peptide-1 analogue
OT  - insulin therapy
OT  - network meta-analysis
OT  - systematic review
EDAT- 2019/08/31 06:00
MHDA- 2021/05/21 06:00
CRDT- 2019/08/31 06:00
PHST- 2019/03/13 00:00 [received]
PHST- 2019/08/08 00:00 [revised]
PHST- 2019/08/28 00:00 [accepted]
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2021/05/21 06:00 [medline]
PHST- 2019/08/31 06:00 [entrez]
AID - 10.1111/dom.13871 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2020 Jan;22(1):107-115. doi: 10.1111/dom.13871. Epub 2019 
      Oct 7.